Start Time: 08:30 January 1, 0000 9:05 AM ET

Ocugen, Inc. (NASDAQ:OCGN)

Q1 2023 Earnings Conference Call

May 05, 2023, 08:30 AM ET

Company Participants

Shankar Musunuri - Chairman, CEO and Co-Founder

Quan Vu - CFO and Chief Business Officer

Sharon Choe - Head of IR

Conference Call Participants

Jennifer Kim - Cantor Fitzgerald

Jonathan Aschoff - ROTH Capital Partners

Uy Ear - Mizuho Securities

Robert LeBoyer - Noble Capital Markets

Swayampakula Ramakanth - H.C. Wainwright

Daniil Gataulin - Chardan

Operator

Good morning, and welcome to the Ocugen's First Quarter 2023 Financial Results and Business Update Call. Please note that this call is being recorded at this time. All participant lines are in a listen-only mode. Following the speakers' commentary, there will be a question-and-answer session.

I will now turn the call over to Sharon Choe, Ocugen's Head of Investor Relations. You may begin.

Sharon Choe

Thank you, Monty. Joining me today are Ocugen's Chairman, CEO and Co-Founder, Dr. Shankar Musunuri, who will provide a business update; and our Chief Financial Officer and Chief Business Officer, Quan Vu, who will provide a financial update.

Earlier this morning, we issued a press release detailing business and operational highlights for the first quarter of 2023. We encourage listeners to review the press release, which is available on our Web site at www.ocugen.com. This call is being recorded, and a replay with the accompanying slide presentation will be available on the Investors section of the Ocugen Web site for approximately 45 days.

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as predict, believe, potential, propose, continue, estimate, anticipate, expect, plan, intend, may, could, might, will, should, or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties and may cause actual events or results to differ materially from our current expectations. Investors should familiarize themselves with the company's filings for complete details. Except as required by law, we assume no obligation to update forward-looking statements contained in this presentation, whether as a result of new information, future events or otherwise after the date of this presentation. Finally, Ocugen's quarterly report on Form 10-Q covering the first quarter of 2023 will be filed soon after today's call.